These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 3669779)

  • 1. Phase I clinical and pharmacokinetic study of orally administered N4-palmitoyl-1-beta-D-arabinofuranosylcytosine.
    Ohno R; Kimura K; Ota K; Miura Y; Hoshino A; Hattori K; Hirano M; Ito M; Maekawa T; Nakamura T
    Med Oncol Tumor Pharmacother; 1987; 4(2):67-73. PubMed ID: 3669779
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Treatment of myelodysplastic syndromes (MDS) with oral administration of N4-palmitoyl-1-beta-D-arabinofuranosyl cytosine (PLAC)].
    Ohno R; Kimura K
    Gan To Kagaku Ryoho; 1988 Apr; 15(4 Pt 2-2):1205-8. PubMed ID: 3382195
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I clinical and pharmacokinetic study of N4-behenoyl-1-beta-D-arabinofuranosylcytosine.
    Kimura K; Ohno R; Amaki I; Hattori K; Hirota Y; Hoshino A; Ichimaru M; Ito M; Kimura I; Maekawa T
    Med Oncol Tumor Pharmacother; 1986; 3(1):15-24. PubMed ID: 3702507
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical pharmacology of N4-palmitoyl-1-beta-D-arabinofuranosylcytosine in patients with hematologic malignancies.
    Ueda T; Nakamura T; Kagawa D; Uchida M; Domae N; Sugiyama M; Ueda Y; Sasada M; Uchino H
    Cancer Chemother Pharmacol; 1989; 24(6):371-5. PubMed ID: 2791191
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I--II study of N4-behenoyl-1-beta-D-arabinofuranosylcytosine.
    Kimura K; Yamada K; Uzuka Y; Maekawa T; Takaku F; Shimoyama M; Ogawa M; Amaki I; Osamura S; Ito M; Sakai Y; Oguro M; Hattori K; Hoshino A; Hirota Y; Ohta K; Nakamura T; Masaoka T; Kimura I; Ichimaru M
    Recent Results Cancer Res; 1981; 76():232-40. PubMed ID: 7232852
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oral topotecan given once or twice daily for ten days: a phase I pharmacology study in adult patients with solid tumors.
    Gerrits CJ; Burris H; Schellens JH; Eckardt JR; Planting AS; van der Burg ME; Rodriguez GI; Loos WJ; van Beurden V; Hudson I; Fields S; Von Hoff DD; Verweij J
    Clin Cancer Res; 1998 May; 4(5):1153-8. PubMed ID: 9607572
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antitumor effects and pharmacology of orally administered N4-palmitoyl-1-beta-D-arabinofuranosylcytosine in mice.
    Hori K; Tsuruo T; Naganuma K; Tsukagoshi S; Sakurai Y
    Cancer Res; 1984 Jan; 44(1):172-7. PubMed ID: 6690034
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacologic and clinical studies of N4-behenoyl-1-beta-D-arabinofuranosylcytosine.
    Yamada K; Kawashima K; Kato Y; Morishima Y; Tanimoto M; Ohno R
    Recent Results Cancer Res; 1980; 70():219-29. PubMed ID: 6766563
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Clinical and pharmacokinetic studies of high dose N4-behenoyl-1-beta-D-arabinofuranosylcytosine].
    Yoshida T; Nakamura S; Ohtake S; Ito K; Kobayashi K; Kanno M; Hirai J; Tachimori K; Matsuda T
    Gan To Kagaku Ryoho; 1987 Jun; 14(6 Pt 1):1820-4. PubMed ID: 3592717
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [The clinical phase I study of TNP-351. The TNP-351 Research Committee].
    Taguchi T; Niitani H; Furue H; Tsukagoshi S; Kanamaru R; Hasegawa K; Akazawa S; Yoneda S; Tominaga T; Sasaki T
    Gan To Kagaku Ryoho; 1995 Feb; 22(2):259-71. PubMed ID: 7857102
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Phase I study of YNK01 (1-beta-D-arabinofuranosylcytosine-5'-stearylphosphate)].
    Fukuoka M; Miyazaki T; Yoshida Y; Hattori M; Niitani H; Nakamura T; Hirota Y; Ohta K; Tanaka M; Suzuoki Y
    Gan To Kagaku Ryoho; 1990 Nov; 17(11):2213-9. PubMed ID: 2241185
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of leukemia and myelodysplastic syndromes with orally administered N4-palmitoyl-1-beta-D-arabinofuranosylcytosine.
    Ohno R; Hirano M; Yamagata K; Ohara K; Shirakawa S; Hirota Y; Kobayashi M; Yoshikawa S; Mitomo Y; Ikeda Y
    Cancer Chemother Pharmacol; 1986; 17(2):161-4. PubMed ID: 3719896
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I and pharmacokinetic study of triapine, a potent ribonucleotide reductase inhibitor, administered daily for five days in patients with advanced solid tumors.
    Murren J; Modiano M; Clairmont C; Lambert P; Savaraj N; Doyle T; Sznol M
    Clin Cancer Res; 2003 Sep; 9(11):4092-100. PubMed ID: 14519631
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A comparison of clinical pharmacodynamics of different administration schedules of oral topotecan (Hycamtin).
    Gerrits CJ; Schellens JH; Burris H; Eckardt JR; Planting AS; van der Burg ME; Rodriguez GI; Loos WJ; van Beurden V; Hudson I; Von Hoff DD; Verweij J
    Clin Cancer Res; 1999 Jan; 5(1):69-75. PubMed ID: 9918204
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Continuous infusion of high-dose 1-beta-D-arabinofuranosylcytosine: a phase I and pharmacological study.
    Spriggs DR; Robbins G; Takvorian T; Kufe DW
    Cancer Res; 1985 Aug; 45(8):3932-6. PubMed ID: 4016760
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Early phase II study of PL-AC [N4-palmitoyl-(1-beta-D-arabinofuranosyl) cytosine] on hematopoietic malignancies].
    Takubo T; Kubota Y; Tanaka T; Ueda T; Shibata H; Nakamura H; Masaoka T; Yoshitake J; Ishigami S
    Gan To Kagaku Ryoho; 1983 Feb; 10(2 Pt):283-9. PubMed ID: 6576729
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of acute myelogenous leukemia in adults with N4-behenoyl-1-beta-D-arabinofuranosylcytosine.
    Kimura K; Ohno R; Amaki I; Hattori K; Hirota Y; Hoshino A; Ichimaru M; Ito M; Kimura I; Maekawa T
    Cancer; 1985 Oct; 56(8):1913-7. PubMed ID: 3861233
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Phase I study of 5'-deoxy-5-fluorouridine (5'-DFUR)].
    Nakao I; Saito T; Kimura K; Wakui A; Yokoyama M; Kanamaru R; Furue H; Komita T; Ohta K; Murakami M
    Gan To Kagaku Ryoho; 1985 Oct; 12(10):2037-43. PubMed ID: 2932058
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I clinical and pharmacokinetic study of trimetrexate using a daily x5 schedule.
    Stewart JA; McCormack JJ; Tong W; Low JB; Roberts JD; Blow A; Whitfield LR; Haugh LD; Grove WR; Lopez AJ
    Cancer Res; 1988 Sep; 48(17):5029-35. PubMed ID: 2970294
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I trial and pharmacokinetics of trimelamol (N2,N4,N6-trihydroxymethyl-N2,N4,N6-trimethylmelamine).
    Judson IR; Calvert AH; Rutty CJ; Abel G; Gumbrell LA; Graham MA; Evans BD; Wilman DE; Ashley SE; Cairnduff F
    Cancer Res; 1989 Oct; 49(19):5475-9. PubMed ID: 2670205
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.